Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
BIOGEN NZ BIOPHARMA LIMITED,Natalizumab (subcutaneous administration),Relapsing-remitting multiple sclerosis (RRMS),Natalizumab (subcutaneous administration) (TYSABRIÂ®),Only if cost neutral or cost saving,Community and Hospital,Nervous System
